Replies to post #693265 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Sorry that ChatGPT reply was not for after trial is completed that was during trial I believe

Here is chatGPT reply for reporting IA after trial is over

Pharmaceutical companies may report interim analysis results of a trial after the trial is over, but this depends on several factors:

1. **Scientific Publications**: Companies often publish the full results of a clinical trial in scientific journals, which may include interim analysis data as part of the comprehensive report on the study.

2. **Regulatory Submissions**: When submitting a new drug application to regulatory authorities (like the FDA or EMA), companies include all relevant data, including interim analyses, in their submissions.

3. **Transparency Initiatives**: Many companies commit to transparency initiatives, such as registering trials and reporting results on public databases (like ClinicalTrials.gov). This can include interim analysis data.

4. **Investor and Public Communication**: Companies may release interim analysis results as part of their communications to investors and the public, especially if the data are significant and impact the understanding of the trial's outcomes.

5. **Post-Trial Reviews and Meta-Analyses**: Researchers may conduct post-trial reviews or meta-analyses that include interim analysis data to provide a more comprehensive understanding of the trial results.

While interim results are more commonly discussed during the trial to guide its progress, their inclusion in post-trial reports and publications ensures a complete and transparent presentation of the study's findings.